Looks like they found a few targets there. I believe the next trials will be on earlier stage patients and on the identified target cancers. Looking good. From the web site. "Perth, Australia. 21 June 2006: Solbec Pharmaceuticals (ASX: SBP) is pleased to announce that the complete results of its Phase I cancer clinical trial of Coramsine® for the treatment of advanced solid tumours have been presented at the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta Georgia. These results have also been published in the Journal of Clinical Oncology (Citation: Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 2070). A link to the abstract has been posted on Solbec’s website in the “Investor Relations” section. The complete Phase I results detailed the 2-hour, 4-hour and 24-hour infusion groups, 27 patients in total. No myelosuppression or other serious drug-related toxicity was recorded and partial responses were documented in three of the eight patients receiving six or more cycles of Coramsine® therapy ( responses were seen in: renal cell carcinoma, non-small cell lung cancer and a cancer of unknown primary origin). Responses were noted using both 2-hour and 4-hour infusions. ASCO is the world’s leading professional organisation representing physicians who treat people with cancer. More than 23,000 oncology health care practitioners belong to ASCO, representing all oncology disciplines. As such, Solbec’s presentation is an important factor in developing awareness in the world’s specialist medical and scientific community of Coramsine’s® clinical progress."
SBP Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
